Health

Health
Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it is working to start a Phase III clinical trial in Japan with the humanized anti-human IL-6 receptor monoclonal antibody, “Actemra® Intravenous Infusion 80 mg, 200 mg, and 400 mg” [generic name: tocilizumab (genetical recombination)] in COVID-19 pneumonia.
Japan's cosmetics makers and distillers rush to make sanitizers
Japanese cosmetics and household goods companies as well as alcoholic beverage makers are moving to increase production of hand disinfectant in response to a request by Prime Minister Shinzo Abe to help alleviate shortages caused by heavy demand due to the coronavirus.
Suntory offers big bucks to techies who can personalize drinks
Suntory Holdings has begun dangling annual salaries in the hundreds of thousands of dollars to lure technology talent for its digital transformation, as the Japanese beverage maker leverages data to move beyond the 20th-century model of mass production for mass consumption.
Beyond N95: Industrial filters create particle-capturing masks
Yamashin-Filter, a Japanese manufacturer of filters for construction machinery, has developed a high performance replaceable face mask insert boasting extended particle-blocking performance and plans to ramp up mass production of its own mask next month as demand for protection soars with the spread of the novel coronavirus.